The United Kingdom and the United States have established a important trade agreement that will keep zero duties on British pharmaceutical products being sold in the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to increase spending on medicines through the National Health Service (NHS). This move guarantees that import taxes on these vital products will stay at nothing for a timeframe of three years.
This agreement is in response to earlier statements to significantly raise import taxes on patented pharmaceutical products, with potential rates mentioned as high as 100%.
"This agreement with the Britain bolsters the worldwide climate for cutting-edge drugs and establishes long-overdue fairness to American-British pharmaceutical trade," a statement noted.
Economic Impact
Medicines represent one of the UK's largest exports to the US, which is easily the largest buyer for major UK drugmakers.
Trade data reveal that in the one-year period leading up to last September, the UK sold drugs worth £11.1bn to the US. This figure accounted for nearly one-fifth of total UK exports in that timeframe.
"This agreement protects jobs, stimulates investment and sets the stage for the UK to establish itself as a worldwide center for medical research," a government official remarked.
Detailed British Pledges
The deal entails several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the cost ceiling at which it considers new therapies to be too expensive by a quarter.
- Boosted Medicine Funding: There is a goal to raise overall health service expenditure on drugs from 0.3% of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The amount drug companies must refund to the NHS to control costs will be restricted at 15%. Last year, rebates topped twenty percent.
Recent Tensions
This agreement takes place against a ongoing dispute between the pharmaceutical industry and the UK government over drug pricing and approval rates.
The disagreement were exacerbated by claims that US customers were paying a premium for the same drugs than people in the Britain and the EU.
In recent months, several large pharmaceutical investments in the UK have been paused or cancelled, while major funding commitments have been announced toward US facilities.
One official publicly accepted that the NHS needed to spend more on drugs, noting that its spending on drugs had shrunk as a share of its overall budget over the last ten years.
